Drug Profile
Trastuzumab biosimilar - Hetero Drugs
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Hetero Drugs
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Breast cancer in India (IV)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Breast-cancer in India (IV, Infusion)
- 26 Sep 2019 Hetero Drugs plans the phase III TRUMAB trial for Breast cancer (Combination therapy, Metastatic disease) in India (CTRI2019-03-018009)